

Bibliography

1. International Diabetes Federation. IDF Diabetes Atlas. 7th edition. 2013. Available from: <http://www.diabetesatlas.org>
2. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. *Australas Med J*. 2014;7(1):45–8.
3. Mohan V, Pradeepa R. Epidemiology of Diabetes in Different Regions of India. *Heal Adm*. 2009;22(1):1–18.
4. Pickup J. Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. *Diabetes Care*. 2004;27(3):813–23.
5. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes Mellitus and Inflammation. *Curr Diab Rep*. 2013 Jun 14;13(3):435–44.
6. Zhu C. Aldose Reductase Inhibitors as Potential Therapeutic Drugs of Diabetic Complications. Intech open access publisher.2013.
7. Garapelli R, Rao AR, Veeresham C. Aldose Reductase Inhibitory Activity of *Butea monosperma* for the Management of Diabetic Complications. *Pharmacologia*. 2015;6(8):355–9.
8. Palanisamy UD. Plants as Effective Agents in Treating Diabetes and Its Complications. *J Nutrition Health Food Sci* 2014;2(2): 1-2.
9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 1997 Jul;20(7):1183–97.
10. American Diabetes Association. Standards of medical care in diabetes—2012. *Diabetes care*. 2012 Jan 1;35(Supplement 1):S11-63.
11. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258).
12. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. *Diabetes Spectr*. 2004;17(3):183 LP-190.

13. Boron WF. Medical physiology. Elsevier Health Sciences; 2005. 1141-1172.
14. Dodson G, Steiner D. The role of assembly in insulin's biosynthesis. *Current opinion in structural biology*. 1998 Apr 1;8(2):189-94.
15. Steiner DF. Chemistry and biosynthesis of the islet hormones: insulin, islet amyloid polypeptide (amylin), glucagon, somatostatin, and pancreatic polypeptide. *Endocrinology*. 2001;1:667-88.
16. Sato Y, Aizawa T, Komatsu M, Okada N, Yamada T. Dual functional role of membrane depolarization/Ca²⁺ influx in rat pancreatic B-cell. *Diabetes*. 1992 Apr 1;41(4):438-43.
17. Bratanova-Tochkova T, Cheng H, Daniel S, Gunawardana S, Liu Y, Mulvaney-Musma J, et al. Triggering and augmentation mechanism, granule pool, and biphasic insulin secretion. *Diabetes*. 2002;51:S83-90.
18. Patti ME, Kahn CR. The insulin receptor--a critical link in glucose homeostasis and insulin action. *J Basic Clin Physiol Pharmacol*. 1998;9(2-4):89-109.
19. Homsy M Al, Lukic M. An Update on the pathogenesis of Diabetes Mellitus. *Med Microbiol.Immunology Unit*. 1992;
20. Jun H, Chung Y, Han J, Kim A, Yoo S, Sherwin R. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. *Diabetologia*. 2002;45:668-76.
21. Nerup J, Mandrup-Poulsen T, Mølviig J, Helqvist S. Mechanisms of pancreatic beta-cell destruction in type I diabetes. *Diabetes*. 1987;11:16-23.
22. Sarvetnick N, Liggitt D, Pitts S, Hansen S, Stewart T. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. *Cell*. 1988;52:773-82.
23. Lukic M, Stosic-Grujicic S, Ostojic N, Chan W. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. *Biochem*. 1991;178(3):913-20.
24. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. *Diabetologia*. 1992;35(11):1060-7.

-
25. Pinkney J, Sjostrom C, Gale E. Should surgeons treat diabetes in severely obese people? *Lancet*. 2001;357:1357.
 26. Ye J. Mechanisms of insulin resistance in obesity. *Front Med*. 2013;7:14–24.
 27. Ali A, Ferris W, Naran N. Insulin resistance in the control of body fat distribution: a new hypothesis. *Horm Metab*. 2011;43:77–80.
 28. Wiklund P, Toss F, Weinehall L. Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. *J*. 2008;93:4360–6.
 29. Yamashita S, Nakamura T, Shimomura I, Nishida M. Insulin resistance and body fat distribution. *Diabetes*. 1996;19:287–91.
 30. Kaplan N. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med*. 1989;149:1514–1520.
 31. Ye J. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. *Endocrine, Metab Immune Disord*. 2007;7:65–74.
 32. Antuna-Puente B, Feve B, Fellahi S, Bastard J. Adipokines: the missing link between insulin resistance and obesity. *Diabetes Metab*. 2008;34:2–11.
 33. Kralisch S, Sommer G, Deckert C, Linke A. Adipokines in diabetes and cardiovascular diseases. *endocrinologica*. 2007;32:161–71.
 34. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. *Curr Mol Med*. 2005;5:333–9.
 35. Kim J, Bachmann RA, Chen J. Chapter 21 Interleukin- 6 and Insulin Resistance. *Vitam Horm*. 2009;80:613–33.
 36. Weigert C, Hennige AM, Brodbeck K, Häring HU, Schleicher ED. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. *Am J Physiol - Endocrinol Metab*. 2005;289(2).

37. Yaturu S, Daberry RP, Rains J, Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. *Cytokine*. 2006;34(3):219–23.
38. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity. *Biochem Biophys Res Commun*. 1999;257(1):79–83.
39. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. *Arterioscler Thromb Vasc Biol*. 2000;20(6).
40. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of Hypoadiponectinemia With Coronary Artery Disease in Men. *Arterioscler Thromb Vasc Biol*. 2003;23(1).
41. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress. *Circulation*. 2007;115(11):1408-16
42. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue. *Circulation*. 2003;107(5):671-4.
43. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. *Gastroenterology*. 2003;125(6):1796–807.
44. Valle M, Martos R, Gascón F, Cañete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. *Diabetes Metab*. 2005 Feb;31(1):55–62.
45. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell. *Circulation*. 2002;105(24):2893-8

-
46. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages. *Circulation*. 2001;103(8):1057-63
 47. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, et al. Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages. *Circulation*. 2004;109(17):2046-9
 48. Neumeier M, Weigert J, Schäffler A, Wehrwein G, Müller-Ladner U, Schölmerich J, et al. Different effects of adiponectin isoforms in human monocytic cells. *J Leukoc Biol*. 2006 Apr;79(4):803–8.
 49. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. *Immunology*. 2001 Jun;103(2):131–6.
 50. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. *J Immunol*. 1991;147(11):3815-22.
 51. Ropelle ER, Flores MB, Cintra DE, Rocha GZ, Pauli JR, Morari J, et al. IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKKbeta and ER stress inhibition. *PLoS Biol*. 2010 Aug 24;8(8).
 52. Hong E-G, Ko HJ, Cho Y-R, Kim H-J, Ma Z, Yu TY, et al. Interleukin-10 Prevents Diet-Induced Insulin Resistance by Attenuating Macrophage and Cytokine Response in Skeletal Muscle. *Diabetes*. 2009;58(11):2525-35
 53. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin -10 and Related Cytokines and Receptors. *Annu Rev Immunol*. 2004 Apr;22(1):929–79.
 54. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. *EMBO J*. 1996 Apr 1;15(7):1557–65.

55. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer. *J Immunol.* 2002;168(12):6479-85.
56. Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. *J Exp Med.* 1994;179(4):1379-84
57. Lowell BB, Shulman GI. Mitochondrial Dysfunction and Type 2 Diabetes. *Science.* 2005;307(5708):384-7
58. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. *J Clin Invest.* 2002;109(10):1345–50.
59. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic β -cells. *Nature.* 2001 Dec 13;414(6865):807–12.
60. Maassen JA, 't Hart LM, van Essen E, Heine RJ, Nijpels G, Jahangir Tafrechi RS, et al. Mitochondrial Diabetes. *Diabetes.* 2004;53(1):103-9
61. Corkey BE. Banting Lecture 2011. *Diabetes.* 2011;61(1):4-13
62. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu K-Y, Hu X, et al. Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production. *Cell Metab.* 2012;16(6):723–37.
63. Ozcan U, Cao Q, Yilmaz E, Lee A-H, Iwakoshi NN, Ozdelen E, et al. Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes. *Science.* 2004;306(5695):457-61
64. Schröder M, Kaufman RJ. ER stress and the unfolded protein response. *Mutat Res Mol Mech Mutagen.* 2005;569(1):29–63.
65. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes. *Science (80-).* 2006;313(5790):1137-40
66. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes care.* 1991 Mar 1;14(3):173-94.

67. Kaku K. Pathophysiology of Type 2 Diabetes and Its Treatment Policy. *JMAJ*. 2010;53(531):41–6.
68. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β -Cell Deficit and Increased β -Cell Apoptosis in Humans With Type 2 Diabetes. *Diabetes*. 2003;52(1):102-10
69. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001 Dec 13;414(6865):813–20.
70. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van Den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. *Diabetes*. 1993 Jun 1;42(6):801-13.
71. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. *Science*. 1996 May 3;272(5262):728–31.
72. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. *Diabetologia*. 1994 Feb;37(2):141–4.
73. Sima AAF, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, et al. Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with Sorbinil. *N Engl J Med*. 1988 Sep 1;319(9):548–55.
74. Greene DA, Arezzo JC, Brown MB, Group the ZS. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. *Zenarestat Study Group. Neurology*. 1999 Aug 11;53(3):580–91.
75. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. *J Clin Invest*. 1994 Jul;94(1):110–7.
76. Tilton RG. Diabetic vascular dysfunction: Links to glucose-induced reductive stress and VEGF. *Microsc Res Tech*. 2002 Jun 1;57(5):390–407.

-
77. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. *Am J Pathol.* 1997 Feb;150(2):523–31.
 78. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. *J Clin Invest.* 1997 Dec 15;100(12):2995–3004.
 79. Tan KCB, Chow W-S, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced Glycation End Products and Endothelial Dysfunction in Type 2 Diabetes. *Diabetes Care.* 2002;25(6).
 80. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. */data/revues/12623636/00270005/535/.* 2008;
 81. Schmidt AM, Yan S Du, Wautier J-L, Stern D. Activation of Receptor for Advanced Glycation End Products. *Circ Res.* 1999;84(5):489-97
 82. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. *J Clin Invest.* 1996 Jan 1;97(1):238–43.
 83. Brownlee, MD M. Advanced protein glycosylation in diabetes and aging. *Annu Rev Med.* 1995 Feb;46(1):223–34.
 84. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. *Diabetologia.* 1992 Jan;35(1):96–7.
 85. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, et al. High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells. *Circulation.* 2003;107(7).
 86. Cardillo C, Campia U, Bryant MB, Panza JA. Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus. *Circulation.* 2002;106(14):1783-7
-

-
87. Nerlich AG, Sauer U, Kolm-Litty V, Wagner E, Koch M, Schleicher ED. Expression of Glutamine:Fructose-6-Phosphate Amidotransferase in Human Tissues: Evidence for High Variability and Distinct Regulation in Diabetes. *Diabetes*. 1998;47(2):170-8
 88. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. *J Mol Med*. 1997 Dec 2;76(1):21–31.
 89. Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. *Invest Ophthalmol Vis Sci*. 1997;38(13):2711–20.
 90. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. *Diabet Med*. 2001 Dec;18(12):945–59.
 91. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, et al. Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells. *Circulation*. 2002;106(4):466-72
 92. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. *Am J Med*. 1998;105(1):4S–14S.
 93. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat. *Diabetes*. 1991;40(10):1328-34
 94. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, A Novel Inhibitor of Advanced Glycation. *Diabetes*. 1997;46(5):895-9
 95. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. *Proc Natl Acad Sci U S A*. 1991 Dec 15;88(24):11555–8.
-

-
96. Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. *Proc Natl Acad Sci U S A*. 1995 Mar 28;92(7):2780–4.
 97. Du X-L, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci*. 2000 Oct 24;97(22):12222–6.
 98. Brownlee M, Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000 Apr 13;404(6779):787–90.
 99. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. *Diabetes Care*. 2004 Jan;27 Suppl 1:S84-7.
 100. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. *Vascul Pharmacol*. 2002;39(4):213–23.
 101. Aveleira CA, Lin C-M, Abcouwer SF, Ambrósio AF, Antonetti DA. TNF- α Signals Through PKC ζ /NF- κ B to Alter the Tight Junction Complex and Increase Retinal Endothelial Cell Permeability. *Diabetes*. 2010;59(11):2872-82
 102. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. *Br J Ophthalmol*. 2004 Oct;88(10):1343–7.
 103. Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. *Diabetol Metab Syndr*. 2009;1(1):10.
 104. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. *Am J Kidney Dis*. 1999;33(3):458–63.
 105. Navarro JF, Mora C, Maciá M, García J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. *Am J Kidney Dis*. 2003;42(1):53–61.
-

106. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. *J Am Soc Nephrol*. 2005 Mar;16(8):S78-82.
107. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. *Immunol Today*. 1990 Jan;11:443–9.
108. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth Factor- β 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. *Am J Kidney Dis*. 1999;34(5):818–23.
109. Sharma K, Ziyadeh FN. Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor- β as a Key Mediator. *Diabetes*. 1995;44(10):1139-46
110. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. *Diabetes*. 2005 Aug;54(8):2320–7.
111. Isaka Y, Akagi Y, Ando Y, Imai E. Application of gene therapy to diabetic nephropathy. *Kidney Int Suppl*. 1997 Sep;60:S100-3.
112. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF- κ B in Tubular Epithelial Cells of Rats With Intense Proteinuria: Role of Angiotensin II and Endothelin-1. *Hypertension*. 2001;37(4):1171–8.
113. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF- κ B activation and overexpression of regulated genes in human diabetic nephropathy. *Nephrol Dial Transplant*. 2004 Oct 1;19(10):2505–12.
114. Tapp R SJ. Epidemiology of diabetic neuropathy:Explore our Research. In Tesfaye S BA, editor. United states: Oxford University Press, United States 2009:1-8.
115. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic Neuropathies. *Diabetes Care*. 2005;28(4).

116. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? *Indian J Endocrinol Metab.* 2016;20(4):546–51.
117. Boyle PJ. Diabetes Mellitus and Macrovascular Disease: Mechanisms and Mediators. *Am J Med.* 2007;120(9):S12–7.
118. Saklani A, Parcha V, Dhulia IS, Kumar DE. Combined effect of *Coccinia indica* (Wight & Arn) and *Salvadora oleoides* (Decne) on blood glucose level and other risk factors associated with type 2 diabetes mellitus in alloxan induced diabetic rats. *Int J Pharm Pharm Sci.* 2012;4(suppl 4):79-84.
119. DCCT, TDC, CTRG. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329:977–986.
120. American Diabetes Association. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. *Diabetes Care.* 1995 Nov 1;18(11):1415-27.
121. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998;352(9131):837–53.
122. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus. *Diabetes.* 1985;34(3).
123. Karnieli E, Zarnowski MJ, Hissin PJ, Simpson IA, Salans LB, Cushman SW. Insulin-stimulated Translocation of Glucose Transport Systems in the Isolated Rat Adipose Cell. *J Biol Chem.* 1981;256(10):4772–7.
124. Quattrin T, Bélanger A, Bohannon NJV, Schwartz SL. Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 1 Diabetes. *Diabetes Care.* 2004;27(11):2622-7
125. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes. *Diabetes Care.* 2004;27(10):2356-62

126. Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. *Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals*. 2010 Sep 15;3(9):3005–20.
127. Reich A, Abaira C, Lawrence AM. Combined glyburide and insulin therapy in type II diabetes. *Diabetes Res*. 1987 Oct;6(2):99–104.
128. Dixit RK, Bhargava VK. Effect of glibenclamide in gabapentin antinociception. *Indian J Physiol Pharmacol*. 2001 Jan;45(1):127–8.
129. Cocca C, Martín G, Núñez M, Gutiérrez A, Cricco G, Mohamad N, et al. Effect of glibenclamide on N-nitroso-N-methylurea-induced mammary tumors in diabetic and nondiabetic rats. *Oncol Res*. 2005;15(6):301–11.
130. Gastpar H, Weissgerber PW, Enzmann F, Zoltobrocki M. The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide. *Res Exp Med (Berl)*. 1982;180(1):75–84.
131. Obata T, Yamanaka Y. Glibenclamide, an antagonist of ATP sensitive K⁺ channels, blocks free radical generation in the rat myocardium. *Neurosci Lett*. 1998 Nov 20;257(1):57–9.
132. Pari L, Latha M. Protective role of *Scoparia dulcis* plant extract on brain antioxidant status and lipidperoxidation in STZ diabetic male Wistar rats. *BMC Complement Altern Med*. 2004 Nov 2;4(1):16.
133. Elmal?? E, Altan N, Bukan N. Effect of the Sulphonylurea Glibenclamide on Liver and Kidney Antioxidant Enzymes in Streptozocin-Induced Diabetic Rats. *Drugs R D*. 2004;5(4):203–8.
134. Rabbani SI, Devi K, Khanam S. Protective role of glibenclamide against nicotinamide-streptozotocin induced nuclear damage in diabetic Wistar rats. *J Pharmacol Pharmacother*. 2010;1(1):18–23.

135. Kewcharoenwong C, Rinchai D, Utispan K, Suwannasaen D, Bancroft GJ, Ato M, et al. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. *Sci Rep*. 2013 Nov 28;3:3363.
136. Kuruvilla A. Herbal formulations as pharmacotherapeutic agents. *Indian J Exp Biol*. 2002;40(1):7–11.
137. Jarald E, Balakrishnan Joshi S, Chandra Jain D. Diabetes and Herbal Medicines. 2008;7(1):97–106.
138. Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. *Journal of ethnopharmacology*. 2003 Jan 31;84(1):105-8.
139. Asolkar LV, Kakkar KK, Charke OJ. Second supplement to glossary of Indian medicinal plants with active principles. Part-I (A–K)(1965–1981). Publications and Information Directorate (CSIR): New Delhi. 1992.
140. Kumar BD, Mitra A, Manjunatha M. In vitro and in vivo studies of antidiabetic Indian medicinal plants: a review. *J Herbal Med Toxi*. 2009;3(2):9-14.
141. Kamble SM, Kamlakar PL, Vaidya S, Bambole VD. Influence of *Coccinia indica* on certain enzymes in glycolytic and lipolytic pathway in human diabetes. *Indian J Med Sci*. 1998 Apr;52(4):143–6.
142. Taj Eldin IM, Ahmed EM, Elwahab A. preliminary study of the clinical Hypoglycemic effects of *Allium cepa* (Red Onion) in Type 1 and Type 2 Diabetic patients. *Environ Health Insights*. 2010;1(4):71
143. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to *Momordica charantia* (karela). *BMJ*. 1981;282(6279):1823-4.
144. Classics C. Citation Classics of ICMR Research Paper (1950-2010) 556. 2010;556–61.

145. Yoshikawa M, Nishida N, Shimoda H, Takada M, Kawahara Y, Matsuda H. Polyphenol constituents from *Salacia* species: quantitative analysis of mangiferin with alpha-glucosidase and aldose reductase inhibitory activities. *Yakugaku Zasshi*. 2001 May;121(5):371–8.
146. Lee HS. Rat lens aldose reductase inhibitory activities of *Coptis japonica* root-derived isoquinoline alkaloids. *Journal of agricultural and food chemistry*. 2002 Nov 20;50(24):7013-6.
147. Halder N, Joshi S, Gupta S. Lens aldose reductase inhibiting potential of some indigenous plants. *J Ethnopharmacol*. 2003;86(1):113–6.
148. Ortiz-Andrade RR, García-Jiménez S, Castillo-España P, Ramírez-Ávila G, Villalobos-Molina R, Estrada-Soto S. α -Glucosidase inhibitory activity of the methanolic extract from *Tournefortia hartwegiana*: An anti-hyperglycemic agent. *J Ethnopharmacol*. 2007;109(1):48–53.
149. Ivorra M, Paya M, Villar A. Hypoglycemic and Insulin Release Effects of Tormentonic Acid: A New Hypoglycemic Natural Product. *Planta Med*. 1988 Aug 24;54(4):282–6.
150. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. *Phytomedicine*. 1995 Oct;2(2):137–89.
151. Kar A, Choudhary B., Bandyopadhyay N. Preliminary studies on the inorganic constituents of some indigenous hypoglycaemic herbs on oral glucose tolerance test. *J Ethnopharmacol*. 1999;64(2):179–84.
152. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. *J Ethnopharmacol*. 2000;71(1):23–43.
153. Masuda T, Toi Y, Bando H, Maekawa T, Takeda Y, Yamaguchi H. Structural identification of new curcumin dimers and their contribution to the antioxidant mechanism of curcumin. *Journal of agricultural and food chemistry*. 2002 Apr 24;50(9):2524-30.
154. Tzeng-Horng Leu BSP, Ming-Chei Maa BSP. The Molecular Mechanisms for the Antitumorogenic Effect of Curcumin. *Curr Med Chem Agents*. 2002 May 1;2(3):357–70.

155. Fu J, Fu J, Yuan J, Zhang N, Gao B, Fu G, et al. Anti-diabetic activities of *Acanthopanax senticosus* polysaccharide (ASP) in combination with metformin. *Int J Biol Macromol.* 2012;50(3):619–23.
156. Prisilla DH, Balamurugan R, Shah HR. Antidiabetic activity of methanol extract of *Acorus calamus* in STZ induced diabetic rats. *Asian Pac J Trop Biomed.* 2012 Feb;2(2):S941–6.
157. Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic *Allium sativum* Linn. *Indian J Exp Biol.* 1992 Jun;30(6):523–6.
158. Naskar S, Mazumder UK, Pramanik G, Gupta M, Suresh Kumar RB, Bala A, et al. Evaluation of antihyperglycemic activity of *Cocos nucifera* Linn. on streptozotocin induced type 2 diabetic rats. *J Ethnopharmacol.* 2011;138(3):769–73.
159. Oyedemi SO, Adewusi, Aiyegoro, Akinpelu. Antidiabetic and haematological effect of aqueous extract of stem bark of *Azelaia africana* (Smith) on streptozotocin-induced diabetic Wistar rats. *Asian Pac J Trop Biomed.* 2011;1(5):353–8.
160. Kumar R, Pate DK, Prasad SK, Sairam K, Hemalatha S. Antidiabetic activity of alcoholic leaves extract of *Alangium lamarckii* Thwaites on streptozotocin–nicotinamide induced type 2 diabetic rats. *Asian Pac J Trop Med.* 2011 Nov;4(11):904–9.
161. Bellamkonda R, Rasineni K, Singareddy SR, Kasetti RB, Pasurla R, Chippada AR, et al. Antihyperglycemic and antioxidant activities of alcoholic extract of *Commiphora mukul* gum resin in streptozotocin induced diabetic rats. *Pathophysiology.* 2011;18(4):255–61.
162. Ibeh BO, Ezeaja MI. Preliminary study of antidiabetic activity of the methanolic leaf extract of *Axonopus compressus* (P. Beauv) in alloxan-induced diabetic rats. *J Ethnopharmacol.* 2011;138(3):713–6.
163. Pandhare R, Balakrishnan S, Mohite P, Khanage S. Antidiabetic and antihyperlipidaemic potential of *Amaranthus viridis* (L.) Merr. in streptozotocin induced diabetic rats. *Asian Pacific J Trop Dis.* 2012 Jan;2:S180–5.

-
164. Mahendran S, Badami S, Maithili V. Evaluation of antidiabetic effect of embelin from *Embelia ribes* in alloxan induced diabetes in rats. *Biomed Prev Nutr.* 2011;1(1):25–31.
 165. Karthic R, Nagaraj S, Arulmurugan P, Seshadri S, Rengasamy R, Kathiravan K. *Gymnema sylvestre* R. Br. suspension cell extract show antidiabetic potential in Alloxan induced diabetic albino male rats. *Asian Pac J Trop Biomed.* 2012;2(2):S930–3.
 166. Orhan N, Aslan M, Demirci B, Ergun F. A bioactivity guided study on the antidiabetic activity of *Juniperus oxycedrus* subsp. *oxycedrus* L. leaves. *J Ethnopharmacol.* 2012;140(2):409–15.
 167. Osadebe PO, Omeje EO, Nworu SC, Esimone CO, Uzor PF, David EK, et al. Antidiabetic principles of *Loranthus micranthus* Linn. parasitic on *Persea americana*. *Asian Pac J Trop Med.* 2010 Aug;3(8):619–23.
 168. Li PB, Lin WL, Wang YG, Peng W, Cai XY, Su WW. Antidiabetic activities of oligosaccharides of *Ophiopogon japonicus* in experimental type 2 diabetic rats. *Int J Biol Macromol.* 2012;51(5):749–55.
 169. Zhao LY, Lan QJ, Huang ZC, Ouyang LJ, Zeng FH. Antidiabetic effect of a newly identified component of *Opuntia dillenii* polysaccharides. *Phytomedicine.* 2011;18(8):661–8.
 170. Galib G, G G, Verma P, BJ P, PK P. *Tribulus terrestris* linn.: a phyto-pharmacological review. *J Ayurveda Holist Med.* 2013;1(3):37–43.
 171. Gauthaman K, Adaikan PG. Effect of *Tribulus terrestris* on nicotinamide adenine dinucleotide phosphate-diaphorase activity and androgen receptors in rat brain. *J Ethnopharmacol.* 2005;96(1):127–32.
 172. Iacono F, Prezioso D, Illiano E, Ruffo A, Romeo G, Amato B. Observational study: daily treatment with a new compound “tradamixina” plus *serenoa repens* for two months improved the lower urinary tract symptoms. *BMC Surg.* 2012 Nov 15;12(S1):1.
 173. Fluckiger FA, Hanbury D. *Pharmacographia: A history of the principal drugs of vegetable origin, met with in Great Britain and British India.* Macmillan; 1874.
-

174. Yan W, Ohtani K, Kasai R, Yamasaki K. Steroidal saponins from fruits of *Tribulus terrestris*. *Phytochemistry*. 1996;42(5):1417–22.
175. Jabbar A, Nazir A, Khalil J, Ansari NI, Qureshi KM, Javed F. To Compare the Effects of *Tribulus Terrestris* with Furosemide on Urine Volume and Electrolytes. *Ann*. 2012;18(2):196
176. Karimi Jashni H, Malekzadeh Shiravani S, Hoshmand F. The effect of the *Tribulus terrestris* extract on spermatogenesis in the rat. *J Jahrom Univ Med Sci*. 2012;9(4):8–13.
177. Narender T, Khaliq T, Madhur G. 5. Naturally occurring antihyperglycemic and antidyslipidemic agents. *Res Signpost Chall Scope Nat Prod Med Chem*. 2011;37661(2):155–85.
178. Gandhi S, Srinivasan BP, Akarte AS. Potential nephrotoxic effects produced by steroidal saponins from hydro alcoholic extract of *Tribulus terrestris* in STZ-induced diabetic rats. *Toxicol Mech Methods*. 2013 Sep 30;23(7):548–57.
179. Li M, Qu W, Wang Y, Wan H, Tian C. [Hypoglycemic effect of saponin from *Tribulus terrestris*]. *Zhong Yao Cai*. 2002 Jun;25(6):420–2.
180. Li JX, Shi Q, Xiong QB, Prasain J, Tezuka Y, Hareyama T, et al. Tribulusamide A and B, New Hepatoprotective Lignanamides from the Fruits of *Tribulus terrestris*: Indications of Cytoprotective Activity in Murine Hepatocyte Culture. *Planta Med*. 1998 Oct 4;64(7):628–31.
181. Wang J, Zu X, Jiang Y. Five furostanol saponins from fruits of *Tribulus terrestris* and their cytotoxic activities. *Nat Prod Res*. 2009 Oct 15;23(15):1436–44.
182. Li M, Guan Y, Liu J, Zhai F, Zhang X, Guan L. Cellular and molecular mechanisms in vascular smooth muscle cells by which total saponin extracted from *Tribulus terrestris* protects against atherosclerosis. *Cell Physiol Biochem*. 2013;32(5):1299–308.
183. Zhang S, Qu W, Zhong S. [Inhibitory effects of saponins from *Tribulus terrestris* on alpha-glucosidase in small intestines of rats]. *Zhongguo Zhong Yao Za Zhi*. 2006 Jun;31(11):910–3.

-
184. Amin A, Lotfy M, Shafiullah M, Adeghate E. The Protective Effect of *Tribulus terrestris* in Diabetes. *Ann N Y Acad Sci.* 2006 Nov 1;1084(1):391–401.
 185. El-Tantawy WH, Hassanin LA. Hypoglycemic and hypolipidemic effects of alcoholic extract of *Tribulus alatus* in streptozotocin-induced diabetic rats: A comparative study with *T. terrestris* (Caltrop). *Indian J Exp Biol.* 2007;45(9):785–90.
 186. Lamba HS, Bhargava CS, Thakur M, Bhargava S. α -Glucosidase and aldose reductase inhibitory activity in vitro and antidiabetic activity in vivo of *tribulus terrestris* L. (dunal). *Int J Pharm Pharm Sci.* 2011;3(3):270–2.
 187. Raghavendra HG, Sen S, Siva Y, Reddy R, Sridhar C, Chakraborty R, et al. Synergistic activity of *tribulus terrestris* and *annona squamosa* extracts against alloxan induced diabetes and hyperlipidemia in rats. *Pharma science monitor* 2011;2(2):12–23.
 188. Roghani M, Omid Malayeri S, Malayeri S. Effect of *Tribulus Terrestris* Oral Feeding on Learning and Memory in Streptozotocin-diabetic Rats: Investigating the Role of lipid Peroxidation. *J Guilan Univ Med Sci.* 2013;22(85):88–95.
 189. Prabhu N, Hadigal S, Sheetal D U, DS S, Shenoy K A. Effect of *Tribulus Terrestris* on Learning and Memory in Wistar Rats. *Pharmacogn J.* 2014 Jun 13;6(4):68–71.
 190. El-Shaibany A, AL-Habori M, Al-Tahami B, Al- Massarani S. Anti-hyperglycaemic Activity of *Tribulus terrestris* L Aerial Part Extract in Glucose-loaded Normal Rabbits. *Trop J Pharm Res.* 2016 Jan 13;14(12):2263.
 191. Chu S, Qu W, Pang X, Sun B, Huang X. [Effect of saponin from *Tribulus terrestris* on hyperlipidemia]. *Zhong Yao Cai.* 2003 May;26(5):341–4.
 192. NIU Wei, QU Wei-jing, WANG Yu-fei 1, CAO Qun-hua, YU Ling-li PY. Effects of saponins from *tribulus terrestris* l. on insulin resistance and hyperlipidemia in the diet-induced obese rats. *Acta Nutr Sin.* 2006;2.
 193. Jia-gui LIQU, Wei-jing, WEI Shan-qiao, WANG Jie-si, ZHUANG Xiu-yuan GX. Effect of tribu saponin from *Tribulus terrestris* on the lipoprotein lipase and (hepatic) lipase activity in lipid metabolic disorder mice. *Chinese Tradit Pat Med.* 2007;6.
-

194. Patki PS, Sharma RK. Double-blind, placebo-controlled clinical evaluation of an Ayurvedic formulation (GlucCare capsules) in non-insulin dependent diabetes mellitus. *J Ayurveda Integr Med.* 2010;1(1):45
195. Adimoelja PA. Protodioscin from herbal plant *Tribulus terrestris* L improves the male sexual functions, probably via DHEA. *Int J Impot Res.* 1997;9(1):1-70
196. KM A. Effect of protodioscin (*Tribulus terrestris*) on the well-being and sexual response of men with diabetes mellitus.
197. Murthy AR, Dubey SD, Tripathi K. Anti-hypertensive effect of Gokshura (*Tribulus terrestris* Linn.) - A clinical study. *Anc Sci Life.* 2000 Jan;19(3-4):139-45.
198. U LFMS, U AS, Ahmed S. Pharmacological Activities of *Tribulus Terrestris* Linn : a Systemic Review. 2015;4(2):136-50.
199. Mohd J, Javed Akhtar A, Abuzer A, Javed A, Ennus T. Pharmacological scientific evidence for the promise of *Tribulus terrestris*. *Int Res J Pharm.* 2012;3(5):403-6
200. Ahmed KA, Venkataraman B V, Mitra SK. Assessment of a Polyherbal Ayurvedic Medicine for Sexual Activity in Rats. *Indian Drugs.* 1999;9(36):576-82.
201. Hong CH, Hur SK, Oh OJ, Kim SS, Nam KA, Lee SK. Evaluation of natural products on inhibition of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) in cultured mouse macrophage cells. *Journal of Ethnopharmacology.* 2002 Nov 30;83(1):153-9.
202. Sharifi AM, Darabi R, Akbarloo N. Study of antihypertensive mechanism of *Tribulus terrestris* in 2K1C hypertensive rats: Role of tissue ACE activity. *Life Sci.* 2003;73(23):2963-71.
203. Yang L, Lu J, An J, Jiang X. [Effect of *Tribulus terrestris* extract on melanocyte-stimulating hormone expression in mouse hair follicles]. *Nan Fang Yi Ke Da Xue Xue Bao.* 2006 Dec;26(12):1777-9.
204. Aggarwal A, Tandon S, Singla SK, Tandon C. Diminution of oxalate induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystallization in vitro by aqueous extract of *Tribulus terrestris*. *Int braz j urol.* 2010 Aug;36(4):480-9.

205. Lakshmi GD, Kumar PR, Bharavi K, Annapurna P, Rajendar B, Patel PT, et al. Protective effect of *Tribulus terrestris* linn on liver and kidney in cadmium intoxicated rats. *Indian J Exp Biol.* 2012;50(1):141–6.
206. Ranjithkumar R, Prathab Balaji S, Balaji B, Ramesh R V., Ramanathan M. Standardized Aqueous *Tribulus terrestris* (Nerunjil) Extract Attenuates Hyperalgesia in Experimentally Induced Diabetic Neuropathic Pain Model: Role of Oxidative Stress and Inflammatory Mediators. *Phyther Res.* 2013 Nov;27(11):1646–57.
207. Maurya R, Singh R, Deepak M, Handa SS, Yadav PP, Mishra PK. Constituents of *Pterocarpus marsupium*: an ayurvedic crude drug. *Phytochemistry.* 2004;65(7):915–20.
208. Rai MK. AKP and DA. Ethno-medicinal plants used by Gond tribe of Bhanadehi, district Chhindwara, Madhya Pradesh. *AN Annot Bibliogr INDIAN Med.* 2000;3(4):237–41.
209. Mitra J, Joshi T. An isoflavone glycoside from the heartwood of *Pterocarpus marsupium*. *Phytochemistry.* 1982 Jan 1;21(9):2429-30.
210. Dhanabal SP, Kokate CK, Ramanathan M, Kumar EP, Suresh B. Hypoglycaemic activity of *Pterocarpus marsupium* Roxb. *Phyther Res.* 2006 Jan;20(1):4–8.
211. Shah DS. A preliminary study of the hypoglycemic action of heartwood of *Pterocarpus marsupium* roxb. *Indian J Med Res.* 1967 Feb;55(2):166–8.
212. Chakravarthy, Saroj G, Gambhir S, Gode K. Pancreatic beta cell regeneration – a novel antidiabetic mechanism of *Pterocarpus marsupium* roxb. *Indian J Pharmacol.* 2017;12(2):123.
213. Anti-Diabetic Plant *Pterocarpus Marsupium* Roxb. Used By Tribals Of Shahdol District M.P. INDIA. *Imp J Interdiscip Res.* 2016;2(10):2454–1362.
214. Ahmad F, Khan MM, Rastogi AK, Chaubey M, Kidwai JR. Effect of (-)epicatechin on cAMP content, insulin release and conversion of proinsulin to insulin in immature and mature rat islets in vitro. *Indian J Exp Biol.* 1991 Jun;29(6):516–20.

215. Manickam M, Ramanathan M, Farboodniay Jahromi MA, Chansouria JP, Ray AB. Antihyperglycemic activity of phenolics from *Pterocarpus marsupium*. *Journal of natural products*. 1997 Jun 23;60(6):609-10.
216. Vats V, Yadav S., Biswas N., Grover J. Anti-cataract activity of *Pterocarpus marsupium* bark and *Trigonella foenum-graecum* seeds extract in alloxan diabetic rats. *J Ethnopharmacol*. 2004;93(2):289–94.
217. Satheesh MA, Pari L. The antioxidant role of pterostilbene in streptozotocin-nicotinamide-induced type 2 diabetes mellitus in Wistar rats. *J Pharm Pharmacol*. 2006 Nov;58(11):1483–90.
218. Rajnish G, Gupta RS. Effect of *pterocarpus marsupium* in streptozotocin-induced hyperglycemic state in rats: comparison with glibenclamide. *Diabetol Croat*. 2009;38(2):39–45.
219. Gayathri M, Kannabiran K. Studies on the Ameliorative Potential of Aqueous Extract of Bark of *Pterocarpus marsupium* Roxb. in Streptozotocin-Induced Diabetic Rats. *J Nat Remedies*. 2010;10(1):36–43.
220. Halagappa K, Girish HN, Srinivasan BP. The study of aqueous extract of *Pterocarpus marsupium* Roxb. on cytokine TNF- α in type 2 diabetic rats. *Indian J Pharmacol*. 2010 Dec;42(6):392–6.
221. Maruthupandian A, Mohan VR. Antidiabetic, antihyperlipidaemic and antioxidant activity of *pterocarpus marsupium* Roxb. in alloxan induced diabetic rats. *Int J PharmTech Res*. 2011;3(3):1681–7.
222. Singh PK, Baxi D, Banerjee S, Ramachandran AV. Therapy with methanolic extract of *Pterocarpus marsupium* Roxb and *Ocimum sanctum* Linn reverses dyslipidemia and oxidative stress in alloxan induced type I diabetic rat model. *Exp Toxicol Pathol*. 2012;64(5):441–8.
223. Gupta M, Edwin S, Soni R, Singhal A. Evaluation of wound healing potential of *Pterocarpus marsupium* heart wood extract in normal and diabetic rats. *Chronicles Young Sci*. 2012;3(1):42.
224. Mishra A, Srivastava R, Srivastava SP, Gautam S, Tamrakar AK, Maurya R, et al. Antidiabetic activity of heart wood of *Pterocarpus marsupium* Roxb. and analysis of phytoconstituents. *Indian J Exp Biol*. 2013;51:363–74.

225. Jahromi MA, Ray AB. Antihyperlipidemic effect of flavonoids from *Pterocarpus marsupium*. *J Nat Prod*. 1993 Jul;56(7):989–94.
226. Grover JK, Vats V, Yadav SS. *Pterocarpus marsupium* extract (Vijayasar) prevented the alteration in metabolic patterns induced in the normal rat by feeding an adequate diet containing fructose as sole carbohydrate. *Diabetes, Obes Metab*. 2005 Jul;7(4):414–20.
227. Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus. Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi. *Indian J Med Res*. 1998 Jul;108:24–9.
228. Rizvi SI, Zaid MA. Intracellular reduced glutathione content in normal and type 2 diabetic erythrocytes: effect of insulin and (-)epicatechin. *J Physiol Pharmacol*. 2001 Sep;52(3):483–8.
229. Rizvi SI, Zaid MA. Insulin-like effect of (-)epicatechin on erythrocyte membrane acetylcholinesterase activity in type 2 diabetes mellitus. *Clin Exp Pharmacol Physiol*. 2001 Sep;28(9):776–8.
230. Hariharan R, Venkataraman S, Sunitha P. Efficacy of vijaysar (*Pterocarpus marsupium*) in the treatment of newly diagnosed patients with type 2 diabetes mellitus: a flexible dose double-blind multicenter randomized controlled trial. *Diabetol Croat*. 2005;1(34):13–20.
231. Saxena A, Vikram NK. Role of Selected Indian Plants in Management of Type 2 Diabetes: A Review. *J Altern Complement Med*. 2004 Apr;10(2):369–78.
232. Devgun, Nanda A, Ansari S. *Pterocarpus marsupium* Roxb. - A comprehensive review. *Pharmacogn Rev*. 2009;3(6):359.
233. Seema G, Vikas G, Baljinder S, Mukesh M, Parveen B. Phytochemistry and pharmacological activities of *pterocarpus marsupium*– a review. *Int Res J Pharm*. 2010;1(11):100–4.
234. Dorababu M, Prabha T, Kumar MM RGMJ. Effects of *Pterocarpus marsupium* on NIDDM-induced rat gastric ulceration and mucosal offensive and defensive factors. *Indian J Pharmacol*. 2004;36(5):296–302.

235. Behera SK, Misra MK. Indigenous phytotherapy for genito-urinary diseases used by the Kandha tribe of Orissa, India. *J Ethnopharmacol.* 2005;102(3):319–25.
236. Krishna V, Manjunatha B, Vidya S, Jagadeesh Singh S, Manohara Y, Raheman A-U, et al. Evaluation of hepatoprotective activity of stem bark of *Pterocarpus marsupium* Roxb. *Indian J Pharmacol.* 2005;37(3):165.
237. Mohire NC, Salunkhe VR, Bhise SB, Yadav A V. Cardiotoxic activity of aqueous extract of heartwood of *Pterocarpus marsupium*. *Indian J Exp Biol.* 2007;45(6):532–7.
238. Mohammadi M, Khole S, Devasagayam TP, Ghaskadbi SS. *Pterocarpus marsupium* extract reveals strong in vitro antioxidant activity. *Drug Discov Ther.* 2009;3(4):151–61.
239. Chakraborty A, Gupta N, Ghosh K, Roy P. In vitro evaluation of the cytotoxic, anti-proliferative and anti-oxidant properties of pterostilbene isolated from *Pterocarpus marsupium*. *Toxicol Vitro.* 2010;24(4):1215–28.
240. Deepa B, Remadevi OK. Ovicidal activity of the wood of *Pterocarpus marsupium* Roxb. (Fabales: Fabaceae) against the teak defoliator, *Hyblaea puera* Cramer. *Curr Biot.* 2011;5(3):370–2.
241. Chauhan B, Chaudhary AK. Memory enhancing activity of methanolic extract of *Pterocarpus marsupium* Roxb. *Phytopharmacology.* 2012;2(1):72–80.
242. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview.
243. Szkudelski T. Streptozotocin–nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. *Exp Biol Med.* 2012 May;237(5):481–90.
244. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. *Pharmacol Rev.* 1970;22(4).
245. Wei M, Ong L, Smith MT, Ross FB, Schmid K, Hoey AJ, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. *Hear Lung Circ.* 2003 Jan;12(1):44–50.

-
246. Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA guidelines for laboratory animal facility. *Indian J Pharmacol.* 2003;35:257–74.
 247. Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. *Journal of ethnopharmacology.* 2003 Jan 31;84(1):105-8.
 248. Newman JD, Turner APF. Home blood glucose biosensors: a commercial perspective. *Biosens Bioelectron.* 2005 Jun;20(12):2435–53.
 249. Groche D, Hoeno W, Hoss G, Vogt B, Herrmann Z, Witzigmann A. Standardization of two immunological HbA1c routine assays according to the new IFCC reference method. *Clin Lab.* 2003;49(11–12):657–61.
 250. Mannheim - Roche in Germany [Internet]. Available from: <https://www.roche.de/en/about/standorte/mannheim/index.html>
 251. Lo S, Russell JC, Taylor AW. Determination of glycogen in small tissue samples. *J Appl Physiol.* 1970 Feb;28(2):234–6.
 252. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med.* 1963 May;61:882–8.
 253. Karasu Ç, Cumaoglu A, Gürpınar A, Kartal M, Kovacicova L, Milackova I, et al. Aldose reductase inhibitory activity and antioxidant capacity of pomegranate extracts. *Interdiscip Toxicol.* 2012 Jan 1;5(1):15–20.
 254. Lowry OH, Rosebrough NJ, Farr AL, Randall, J. R. Protein measurement with Folin Phenol Reagent. *J Biol Chem.* 1951;193:265–75.
 255. Ueda E, Yoshikawa Y, Sakurai H, Kojima Y, Kajiwara NM. In Vitro Alpha-glucosidase Inhibitory Effect of Zn(II) Complex with 6-Methyl-2-picolinmethylamide. *Chem Pharm Bull (Tokyo).* 2005;53(4):451–2.
 256. Singleton VL, Orthofer R, Lamuela-Raventós RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent. *Methods Enzymol.* 1999;299:152–78.
 257. Bhuiyan MAR, Hoque MZ, Hossain SJ. Free Radical Scavenging Activities of *Zizyphus mauritiana*. *World J Agric Sci.* 2009;5(3):318–22.
-

258. Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer's Disease with Combined Amyloid- β and Cerebrovascular Pathology. Ginsberg SD, editor. PLoS One. 2013 Jul 18;8(7):e68612.
259. Sathishsekar D, Subramanian S. Antioxidant properties of Momordica Charantia (bitter gourd) seeds on Streptozotocin induced diabetic rats. Asia Pac J Clin Nutr. 2005;14(2):153–8.
260. Shanmugam KR, Ramakrishna C, Mallikarjuna K, Reddy KS. Protective effect of ginger against alcohol-induced renal damage and antioxidant enzymes in male albino rats. Indian J Exp Biol. 2010;48(2):143–9.
261. Ramudu SK, Korivi M, Kesireddy N, Lee L-C, Cheng I-S, Kuo C-H, et al. Nephro-Protective Effects of a Ginger Extract on Cytosolic and Mitochondrial Enzymes against Streptozotocin (STZ)-Induced Diabetic Complications in Rats. Chin J Physiol. 2011;54(2):79–86.
262. Alnahdi S H. Effect of Rosmarinus Officinalis Extract on some Cardiac Enzymes of Streptozotocin-induced Diabetic Rats. Int J Heal Sci. 2012 Aug 31;2(4):33–7.
263. Divi SM, Bellamkonda R, Kumari Dasireddy S. Evaluation of antidiabetic and antihyperlipedemic potential of aqueous extract of Moringa oleifera in fructose fed insulin resistant and STZ induced diabetic Wistar rats: A comparative study. Asian J Pharm Clin Res. 2002;5(1):67–72.
264. Tribulus terrestris - latest research | Nutriline.org [Internet]. [cited 2017 Feb 13]. Available from: <http://www.nutriline.org/article/99>
265. Ojieh GC, Oluba OM, Erifeta GO, Eidangbe GO. Effect of aqueous root extract of Treculia africana on haemoglobin glycosylation and plasma lipid per oxidation in streptozotocin-induced diabetic rabbits. Int J Plant Physiol Biochem. 2009;1(1):005–8.
266. Rajasekaran S, Sivagnanam K, Subramanian S. Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. Pharmacol Reports. 2005;57:90–6.

267. Tembhurne S, Sakarkar DM. Protective effect of *Murraya koenigii* (L) leaves extract in streptozotocin induced diabetics rats involving possible antioxidant mechanism. *J Med Plants Res.* 2010;4(22):2418–23.
268. Pandhare RB, Sangameswaran B, Mohite PB, Khanage SG. Aqueous extracts of the leaves of *Sesbania sesban* reduces development of diabetic nephropathy in streptozotocin-induced diabetic rat. *Bangladesh J Pharmacol.* 2010 Dec 27;5(2):103–6.
269. Nagappa AN, Thakurdesai PA, Venkat Rao N, Singh J. Antidiabetic activity of *Terminalia catappa* Linn fruits. *J Ethnopharmacol.* 2003;88(1):45–50.
270. Manickam M, Ramanathan M, Farboodniay Jahromi MA, Chansouria JP, Ray AB. Antihyperglycemic activity of phenolics from *Pterocarpus marsupium*. *Journal of natural products.* 1997 Jun 23;60(6):609-10.
271. Bouwens L, Rooman I. Regulation of Pancreatic Beta-Cell Mass. *Physiol Rev.* 2005;85(4):1255–70.
272. Nguyen HT, Kim SM. Three compounds with potent α -glucosidase inhibitory activity purified from Sea Cucumber *Stichopus japonicas*. *SPISE.* 2009;112–22.
273. Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α -Glucosidase Inhibitors for Patients With Type 2 Diabetes. *Diabetes Care.* 2004;28(1):154-63
274. Ali H, Houghton PJ, Soumyanath A. α -Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to *Phyllanthus amarus*. *J Ethnopharmacol.* 2006;107(3):449–55.
275. Du Z, Liu R, Shao W, Mao X, Ma L, Gu L, et al. α -Glucosidase inhibition of natural curcuminoids and curcumin analogs. *Eur J Med Chem.* 2006;41(2):213–8.
276. Bloch K, Vorobeychik M, Yavrians K, Azarov D, Bloch O, Vardi P. Improved activity of streptozotocin-selected insulinoma cells following microencapsulation and transplantation into diabetic mice. *Cell Biol Int.* 2006;30(2):138–43.

277. Apostolidis E, Kwon Y-I, Shetty K. Potential of cranberry-based herbal synergies for diabetes and hypertension management. *Asia Pac J Clin Nutr.* 2006;15(3):433–41.
278. Anis E, Anis I, Ahmed S, Mustafa G, Malik A, Afza N, et al. α -Glucosidase Inhibitory Constituents from *Cuscuta reflexa*. *Chem Pharm Bull (Tokyo).* 2002;50(1):112–4.
279. Pullela S V., Tiwari AK, Vanka US, Vummenthula A, Tatipaka HB, Dasari KR, et al. HPLC assisted chemobiological standardization of α -glucosidase-I enzyme inhibitory constituents from *Piper longum* Linn-An Indian medicinal plant. *J Ethnopharmacol.* 2006;108(3):445–9.
280. Georgetti SR, Casagrande R, Moura-de-Carvalho Vicentini FT, Verri WA, Fonseca MJV. Evaluation of the antioxidant activity of soybean extract by different in vitro methods and investigation of this activity after its incorporation in topical formulations. *Eur J Pharm Biopharm.* 2006;64(1):99–106.
281. Adisakwattana S, Pudhom K, Yibchok-Anun S. Influence of the methanolic extract from *Abutilon indicum* leaves in normal and streptozotocin-induced diabetic rats. *African J Biotechnol.* 2009;8(10):2011–5.
282. Khalil EAM. Biochemical and histopathological studies on the influence of aqueous extract of fenugreek seed (*Trigonella foenum graecum*) on alloxan diabetic male rats. *Egypt J Hosp Med.* 2004;15:83–94.
283. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. *J Am Soc Nephrol.* 2006 May;17(5):1395–404.
284. Parving H-H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. *Kidney Int.* 2006;69(11):2057–63.
285. Vasudevan DM, Sreekumari S, Vaidyanathan K. Textbook of biochemistry for medical students. Jaypee Bros. Medical Publishers; 2011:657.

286. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. *N Engl J Med.* 1993 Nov 11;329(20):1456–62.
287. Anjaneyulu M, Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. *Clin Exp Pharmacol Physiol.* 2004 Apr;31(4):244–8.
288. Rao NK, Nammi S. Antidiabetic and renoprotective effects of the chloroform extract of *Terminalia chebula* Retz. seeds in streptozotocin-induced diabetic rats. *BMC Complement Altern Med.* 2006 Dec 7;6(1):17.
289. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol.* 2004;24(1):32–40.
290. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. *Kidney Int.* 2000 Sep;58:S3–12.
291. Ren H, Chen J, Tan B, Wang D, Lin S, Zhang Y, et al. The disposition and pharmacokinetics of *Dioscorea nipponica* Makino extract in rats. *African J Biotechnol.* 2008;7(22):4015–7.
292. Saleem TM, Saleem TSM, Christina AM, Chidambaranathan N, Ravi V, Gauthaman K. Hepatoprotective activity of *Annona squamosa* Linn. on experimental animal model. *Int J Appl Res Nat Prod.* 2008;1(3):1–7.
293. Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. *Clin Diabetes.* 2005;23(3):115–9.
294. Guven A, Yavuz O, Cam M, Ercan F, Bukan N, Comunoglu C, et al. Effects of melatonin on streptozotocin-induced diabetic liver injury in rats. *Acta Histochem.* 2006;108(2):85–93.
295. Igbedioh S, Akinyele I. Effect of Benomyl Toxicity on Some Liver Constituents of Albino Rats. *Arch Environ Heal An Int J.* 1992 Aug;47(4):314–7.

296. Srivastava S, Pathak PH. Garlic (*Allium sativum*) Extract Supplementation Alters the Glycogen Deposition in Liver and Protein Metabolism in Gonads of Female Albino Rats. *Int J Pharm Sci Drug Res.* 2012;4(2):126–9.
297. Maiti R, Jana D, Das U., Ghosh D. Antidiabetic effect of aqueous extract of seed of *Tamarindus indica* in streptozotocin-induced diabetic rats. *J Ethnopharmacol.* 2004;92(1):85–91.
298. Babu, Gangadevi T, Subramoniam A. Antidiabetic activity of ethanol extract of *cassia kleinii* leaf in streptozotocin-induced diabetic rats and isolation of an active fraction and toxicity evaluation of the extract. *Indian J Pharmacol.* 2017;35(5):290.
299. de Oliveira PRB, da Costa CA, de Bem GF, Marins de Cavalho LCR, de Souza MAV, de Lemos Neto M, et al. Effects of an Extract Obtained From Fruits of *Euterpe oleracea* Mart. in the Components of Metabolic Syndrome Induced in C57BL/6J Mice Fed a High-fat Diet. *J Cardiovasc Pharmacol.* 2010 Dec;56(6):619–26.
300. Zamble A, Carpentier M, Kandoussi A, Sahpaz S, Petrault O, Ouk T, et al. *Paullinia pinnata* Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms. *J Cardiovasc Pharmacol.* 2006 Apr;47(4):599–608.
301. Souza GA, Ebaid GX, Seiva FR, Rocha KH, Galhardi CM, Mani F, Novelli EL. N-Acetylcysteine an *Allium* plant compound improves high-sucrose diet-induced obesity and related effects. *Evidence-Based Complementary and Alternative Medicine.* 2011 Feb 20;2011.
302. Altug T, Yaymaci B, Sati L, Cayli S, Acar G, Altug T, et al. Influence of *Tribulus terrestris* extract on lipid profile and endothelial structure in developing atherosclerotic lesions in the aorta of rabbits on a high-cholesterol diet. *Acta Histochem.* 2009;111(6):488–500.
303. Jung HA, Islam MDN, Kwon YS, Jin SE, Son YK, Park JJ, et al. Extraction and identification of three major aldose reductase inhibitors from *Artemisia montana*. *Food Chem Toxicol.* 2011;49(2):376–84.

304. Sivakumari K, Rathinabai AFMC, Kaleena PK, Jayaprakash P, Srikanth R. Molecular Docking Study of Bark-derived Components of Cinnamomum Cassia on Aldose Reductase. *Indian J Sci Technol.* 2010;3(10):1081–8.
305. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, et al. Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats. *Diabetes.* 2003;52(3):864–71.
306. Srivastava SK, Ramana K V., Bhatnagar A. Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options. *Endocr Rev.* 2005 May;26(3):380–92.
307. Robison WG, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. *Invest Ophthalmol Vis Sci.* 1989;30(11):2285–92.
308. Chakrabarti S, Sima AAF. Effect of Aldose Reductase Inhibition and Insulin Treatment on Retinal Capillary Basement Membrane Thickening in BB Rats. *Diabetes.* 1989;38(9):1181–6.
309. Ahmed MM. Aldose Reductase in the Retina. *Curr Enzym Inhib.* 2007 Feb 1;3(1):49–60.
310. Anderson RS, Trune DR, Shearer TR. Histologic changes in selenite cortical cataract. *Invest Ophthalmol Vis Sci.* 1988;29(9):1418–27.
311. Nishimura C, Lou MF, Kinoshita JH. Depletion of myo-Inositol and Amino Acids in Galactosemic Neuropathy. *J Neurochem.* 1987 Jul;49(1):290–5.
312. Schmidt RE, Plurad SB, Sherman WR, Williamson JR, Tilton RG. Effects of Aldose Reductase Inhibitor Sorbinil on Neuroaxonal Dystrophy and Levels of myo-inositol and Sorbitol in Sympathetic Autonomic Ganglia of Streptozocin-Induced Diabetic Rats. *Diabetes.* 1989;38(5):569–79.
313. Greene DA, Lattimer SA. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. *J Clin Invest.* 1983 Sep;72(3):1058–63.

314. Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA. Polyol Pathway Activity and Myo-Inositol Metabolism: A Suggested Relationship in the Pathogenesis of Diabetic Neuropathy. *Diabetes*. 1983;32(11):988–92.
315. Greene DA, Lattimer SA. Sodium- and energy-dependent uptake of myo-inositol by rabbit peripheral nerve. Competitive inhibition by glucose and lack of an insulin effect. *J Clin Invest*. 1982 Nov;70(5):1009–18.
316. Lim SS, Jung SH, Ji J, Shin KH, Keum SR. Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. *J Pharm Pharmacol*. 2001 May;53(5):653–68.
317. Mathew, Subba-Rao AV. Photooxidation of pterostilbene from *Pterocarpus marsupium* Roxb. *Curr Sci*. 1977;46(10):337–8.
318. Adinarayana D, Syamasundar KV. A new sesquiterpene alcohol from *Pterocarpus marsupium*. *Phytochemistry*. 1982;21(5):1083–5.
319. Veeresham C, Rama Rao A, Asres K. Aldose Reductase Inhibitors of Plant Origin. *Phyther Res*. 2014 Mar;28(3):317–33.
320. Lee SM, Ko I-G, Kim S-E, Kim DH, Kang BN. Protective Effect of Catechin on Apoptosis of the Lens Epithelium in Rats with N-methyl-N-nitrosourea-induced Cataracts. *Korean J Ophthalmol*. 2010 Apr;24(2):101.
321. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. *Korean J Physiol Pharmacol*. 2014 Feb;18(1):1–14.
322. Vangalapati B, Manjrekar PA, Hegde A. Total phenolic content and free radical scavenging activity of *Pterocarpus marsupium* heartwood & *Tribulus terrestris* dry fruits : An in vitro comparative study. 2014;8(5):610–3.
323. Abirami B, Gayathri P, Uma D. In vitro antioxidant potential of *Pterocarpus marsupium* bark. *Int J Chem Pharm Sci*. 2012;3(2):17–24.
324. Kumar Gupta S, Kalaiselvan V, Srivastava S, Saxena R, Sunder Agrawal S. Inhibitory Effect of *Trigonella Foeniculum-Graecum* on Galactose Induced Cataracts in a Rat Model; in vitro and in vivo Studies. *J Ophthalmic Vis Res*. 2009 Oct;4(4):213–9.

325. Tiwari A, Madhusudana Rao. Diabetes mellitus and multiple therapeutic approaches of phytochemical: Present status and future prospects. *Curr Sci.* 2002;83(1):30–8.
326. Packer L. Antioxidants in diabetes management. Dekker; 2000:349.
327. Polidori MC, Mecocci P, Stahl W, Parente B, Cecchetti R, Cherubini A, et al. Plasma levels of lipophilic antioxidants in very old patients with Type 2 diabetes. *Diabetes Metab Res Rev.* 2000 Jan;16(1):15–9.
328. Lee S-R, Suh S-I, Kim S-P. Protective effects of the green tea polyphenol (–)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. *Neurosci Lett.* 2000;287(3):191–4.
329. Biessels G-J, Kamal A, Urban IJ., Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. *Brain Res.* 1998;800(1):125–35.
330. Vangalapati B, Manjrekar PA, Hegde A, Kumar A. Pterocarpus Marsupium heartwood extract restores learning, memory and cognitive flexibility in a stz-na induced diabetes animal model. *Int. J. Pharm. Pharmace. Scie* 2016;8(3):3–7.
331. Vangalapati B, Manjrekar PA, Hegde A, Ullal S. Land Caltrop (*Tribulus terrestris*) Fruit Extract Improves Learning, Memory and Cognitive flexibility in Streptozotocin-Nicotinamide induced Diabetes Animal Model. *Int. J. Pharm. Sci. Rev. Res* 2016;38(44):243–7.
332. Chintawar S., Somani R., Kasture VS, Kasture S. Nootropic activity of *Albizia lebeck* in mice. *J Ethnopharmacol.* 2002;81(3):299–305.
333. Judzewitsch RG, Jaspán JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, et al. Aldose Reductase Inhibition Improves Nerve Conduction Velocity in Diabetic Patients. *N Engl J Med.* 1983 Jan 20;308(3):119–25.
334. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest.* 2006 Jul;116(7):1793–801.
335. Campbell IL, Hobbs M V, Dockter J, Oldstone MB, Allison J. Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. *Am J Pathol.* 1994 Jul;145(1):157–66.

-
336. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes. *Diabetes*. 2005;54(2):114–24.
337. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. *J Biol Chem*. 2003 Nov 14;278(46):45777–84.
338. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin Supplementation Lowers TNF- α , IL-6, IL-8, and MCP-1 Secretion in High Glucose-Treated Cultured Monocytes and Blood Levels of TNF- α , IL-6, MCP-1, Glucose, and Glycosylated Hemoglobin in Diabetic Rats. *Antioxid Redox Signal*. 2009 Feb;11(2):241–9.
339. Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. *Transl Res*. 2007;150(2):101–5.
340. Eitner F, Westerhuis R, Burg M, Weinhold B, Gröne H-J, Ostendorf T, et al. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. *Kidney Int*. 1997 Jan;51(1):69–78.
341. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel Modulator for Endothelial Adhesion Molecules. *Circulation*. 1999;100(25):2473–6.
342. Wong TY, Knudtson MD, Klein R, Klein BE., Meuer SM, Hubbard LD. Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. *Ophthalmology*. 2004;111(6):1183–90.
343. Van Exel E, Gussekloo J, de Craen AJM, Frölich M, Bootsma-van der Wiel A, Westendorp RGJ. Low Production Capacity of Interleukin-10 Associates With the Metabolic Syndrome and Type 2 Diabetes. *Diabetes*. 2002;51(4):1088–92.
344. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka L a, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol*. 2007;8(12):1363–71.
-

345. Kim HJ, Higashimori T, Park SY, Choi H, Dong JY, Kim YJ, et al. Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. *Diabetes*. 2004;53(4):1060–7.
346. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of Acute Changes of Plasma Free Fatty Acids on Intramyocellular Fat Content and Insulin Resistance in Healthy Subjects. *Diabetes*. 2001;50(7):1612–7.
347. Goyal BR, Solanki N, Goyal RK, Mehta AA. Investigation Into the Cardiac Effects of Spironolactone in the Experimental Model of Type 1 Diabetes. *J Cardiovasc Pharmacol*. 2009 Dec;54(6):502–9.
348. Frankish N, de Sousa Menezes F, Mills C, Sheridan H. Enhancement of Insulin Release from the β -Cell Line INS-1 by an Ethanolic Extract of *Bauhinia variegata* and Its Major Constituent Roseoside. *Planta Med*. 2010 Jul 8;76(10):995–7.
349. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. *Diabetes Care*. 2010 Aug;33(8):1859–64.
350. Solanki ND, Bhavsar SK. An evaluation of the protective role of *Ficus racemosa* Linn. in streptozotocin-induced diabetic neuropathy with neurodegeneration. *Indian J Pharmacol*. 2015;47(6):610–5.
351. Poplawski MM, Mastaitis JW, Isoda F, Grosjean F, Zheng F, Mobbs C V. Reversal of Diabetic Nephropathy by a Ketogenic Diet. *Stadler K, editor. PLoS One*. 2011 Apr 20;6(4):e18604.
352. Baquer NZ, Gupta D, Raju J. Regulation of metabolic pathways in liver and kidney during experimental diabetes: Effects of antidiabetic compounds. *Indian J Clin Biochem*. 1998 Jul;13(2):63–80.
353. Nikkilä EA, Kekki M. Plasma triglyceride transport kinetics in diabetes mellitus. *Metabolism*. 1973 Jan;22(1):1–22.